Matches in Nanopublications for { ?s ?p "[Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- assertion description "[Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1230712.RAkhklFY9yeLTDqFFBXaZnGvQP10-mELX6p3jJJkBI_U4130_assertion description "[Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1230712.RAkhklFY9yeLTDqFFBXaZnGvQP10-mELX6p3jJJkBI_U4130_provenance.
- NP1230709.RAzhDEXN06NrLX2NPhg8ZmX5dT4bvqE8CietYFKJV98yU130_assertion description "[Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1230709.RAzhDEXN06NrLX2NPhg8ZmX5dT4bvqE8CietYFKJV98yU130_provenance.
- NP1230710.RAxSlwmo2i0gwNm-__jn4PVvD16vp6_fQ82yPd7AMmICk130_assertion description "[Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1230710.RAxSlwmo2i0gwNm-__jn4PVvD16vp6_fQ82yPd7AMmICk130_provenance.